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interview. For the exposed group, a specific section of the questionnaire is
focused on the occupational history, the description of the procedures (type,
frequency, radiation protection tool) and will be used for the classification into
"comparable exposure level" groups according to estimates of cumulative
dose. For all participants, eye examinations will be performed to specifically
detect cataracts, even in their early stages (lens opacities, LOCS according to
the international standard classification). The analysis will provide an estima-
tion of the risk of cataract in interventional cardiology relative to not-exposed
reference group, taking into account other risk factors. An analysis comparing
the risks according to the level of exposure is also planned.
This epidemiological study will provide further knowledge on the potential
risk of occupational radiation-induced cataracts in cardiology and will contribute
to the awareness of cardiologists in radiation protection. 
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Omega-3 polyunsaturated fatty acids (PUFAs) may reduce vulnerability to
atrial fibrillation (AF). The mechanism underlying this effect is unknown. A
genome wide approach was used to identify gene expression profiles involved
in a new model of vulnerability to AF, and determine whether they were
altered by PUFA therapy. Thirty-six dogs were randomized into 3 groups of
12. Two groups were paced using simultaneous atrial and ventricular pacing
(SAVP) at 220 bpm for 14 days to induce atrial enlargement, fibrosis and sus-
ceptibility to AF. One group was supplemented with oral PUFAs (850 mg/
day) for 21 days, commencing 7 days before the start of pacing (SAVP-
PUFAs); the other received no PUFAs (SAVP-No PUFAs). The final group
was unpaced, unsupplemented and served as controls (CTRL). Atrial tissue
from left appendages was sampled at the end of the protocol. PUFA supple-
mentation caused a 24% increase in tissue phospholipid PUFA concentration.
Gene expression was analyzed via microarray. Results were confirmed with
QT-RT-PCR and histology. SAVP-No PUFAs dogs had significantly
increased mRNA levels of MHCα, elevated levels of other proremodeling
genes Akt, EGF, TIMP1, JAM3 and CD99, and significantly decreased levels
of fibrosis inhibiting Smad6. PUFA supplementation was associated with sig-
nificant down-regulation of Akt, EGF, TIMP1, MHCα, CD99 and lower
JAM3 levels. PUFAs reversed the 34% increase in myocyte cross sectional
area caused by pacing. PUFAs appear to attenuate, at the genetic level, adverse
remodeling in response to mechanical stress.
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